Compound Heterozygous Mutation of Rag1 Leading to Omenn Syndrome

Citation

Published Version
doi:10.1371/journal.pone.0121489

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:15034900

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
Compound Heterozygous Mutation of Rag1 Leading to Omenn Syndrome

Adam G. W. Matthews¹,², Christine E. Briggs³, Keiichi Yamanaka⁴, Trudy N. Small⁵, Jana L. Mooster⁶, Francisco A. Bonilla⁶, Marjorie A. Oettinger⁷, Manish J. Butte⁷*

¹ Department of Molecular Biology, Massachusetts General Hospital and Department of Genetics, Harvard Medical School, Boston, MA 02114, United States of America, ² Department of Biological Sciences, Wellesley College, 106 Central St, Wellesley, MA, 02481, United States of America, ³ Molecular Genetics Core Facility, Children’s Hospital Boston, Boston, MA 02115, United States of America, ⁴ Department of Dermatology, Mie University, Graduate School of Medicine, Mie 514–8507, Japan, ⁵ Bone Marrow Transplant Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, United States of America, ⁶ Department of Pediatrics, Division of Immunology, Allergy, and Rheumatology, Boston Children’s Hospital, Boston, MA 02115, United States of America, ⁷ Department of Pediatrics, Division of Immunology, Allergy, and Rheumatology, Stanford University, 300 Pasteur Drive, Stanford, CA 94305, United States of America

† Deceased.
¤ Current address: GeneSys Research Institute / Tufts University School of Medicine, Boston, United States of America
* manish.butte@stanford.edu

Open Access


Academic Editor: Sebastian D. Fugmann, Chang Gung University, TAIWAN

Received: November 9, 2014
Accepted: February 2, 2015
Published: April 7, 2015

Copyright: © 2015 Matthews et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper.

Funding: This work was supported by National Institutes of Health K08 AI079268 (MJB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

Abstract

Omenn syndrome is a primary immunodeficiency disorder, featuring susceptibility to infections and autoreactive T cells and resulting from defective genomic rearrangement of genes for the T cell and B cell receptors. The most frequent etiologies are hypomorphic mutations in “non-core” regions of the Rag1 or Rag2 genes, the protein products of which are critical members of the cellular apparatus for V(D)J recombination. In this report, we describe an infant with Omenn syndrome with a previously unreported termination mutation (p.R142*) in Rag1 on one allele and a partially characterized substitution mutation (p.V779M) in a “core” region of the other Rag1 allele. Using a cellular recombination assay, we found that while the p.R142* mutation completely abolished V(D)J recombination activity, the p.V779M mutation conferred a severe, but not total, loss of V(D)J recombination activity. The recombination defect of the V779 mutant was not due to overall misfolding of Rag1, however, as this mutant supported wild-type levels of V(D)J cleavage. These findings provide insight into the role of this poorly understood region of Rag1 and support the role of Rag1 in a post-cleavage stage of recombination.

Introduction

During the development of B cells and T cells, a diverse repertoire of antigen receptor genes are assembled from multiple component gene segments in a process known as V(D)J recombination [1]. Each of these gene segments is marked by a recombination signal sequence (RSS) that
is recognized by a complex of the lymphoid-specific proteins Rag1 and Rag2. Together, Rag1 and Rag2 initiate V(D)J recombination by cleaving DNA to generate double-strand breaks consisting of two hairpinned coding ends and two blunt signal ends [2]. The ubiquitously expressed non-homologous end joining (NHEJ) proteins then collaborate with the Rag proteins to rejoin the cleaved DNA molecules, generating precise signal joints and imprecise coding joints [3].

Since antigen receptor gene assembly is required for the proper development of B cells and T cells, mutations that disrupt V(D)J recombination can lead to impaired immune function. Omenn Syndrome (OMIM 603554) is an autosomal recessive variant of severe combined immunodeficiency (SCID) with distinctive clinical features of generalized erythodermia, hepatosplenomegaly, and lymphadenopathy [4]. All patients with SCID are susceptible to infections from common bacteria and viruses as well as opportunistic and fungal pathogens. Unlike patients with classical SCID, patients with Omenn Syndrome have circulating T cells with an abnormal phenotype: they are typically poorly reactive, oligoclonal, and display cell-surface markers of previous activation [5]. B cells are typically absent or low and IgG levels are generally low while IgE levels are high.

Omenn Syndrome can be caused by mutations in Rag1 and Rag2 [6], or rarely by mutations in the NHEJ factor Artemis [7], in the IL-7 receptor alpha chain [8] or in the RNase mitochondrial RNA processing (RMRP) gene [9]. For many patients with Omenn Syndrome, the genetic defect remains unidentified [10]. In general, hypomorphic Rag mutations produce Omenn Syndrome, while null mutations produce T−B−SCID [11,12]. Interestingly, siblings with identical Rag mutations have developed either SCID or Omenn syndrome, suggesting that genetic or environmental effects can modify the phenotype of these disorders [12,13,14]. It has been suggested that early infections may be one factor that leads to the expansion of poorly reactive, oligoclonal T cells and the subsequent development of Omenn Syndrome instead of SCID [15]. Finally, hypomorphic Rag mutations can also cause a distinct SCID phenotype with an expanded pool of γδ T cells [16], combined immunodeficiency with granulomatous disease with or without autoimmunity [17,18], or autoimmune disease of varying severity [19,20,21].

Here, we report a boy with Omenn syndrome diagnosed at ~17 weeks of age. We discovered a maternally-inherited nonsense mutation on one allele of the Rag1 gene. A missense mutation was identified on the other allele in a poorly characterized region of the Rag1 protein. To evaluate this mutation, we performed cellular V(D)J recombination assays, revealing that the maternal nonsense mutation is null, and the paternal missense mutation is severely hypomorphic. However, biochemical assays demonstrate that the paternal missense mutation does not affect catalysis of V(D)J cleavage in vitro, supporting that hypomorphic Rag1 activity in the post-cleavage stages of recombination is sufficient to confer susceptibility to Omenn Syndrome.

Materials and Methods

Clinical laboratory tests

Immunoglobulin levels and PRP and tetanus titers were determined by nephelometry at the Boston Children’s Hospital Chemistry Lab. Pneumococcal titers were determined by the Luminex method at ARUP Reference Laboratory. T cell subsets were determined in the Boston Children’s Hospital Immunology Lab by flow cytometry. T cell proliferations were determined at the University of Iowa using [3H]-thymidine incorporation during the last 24 hours of a 5-day culture. The control numbers for proliferations refer to an internal laboratory control; shipping controls were comparable. This study was approved by the Institutional Review Board at Boston Children’s Hospital. Both parents gave written informed consent.
TCR spectratype assay

TCR spectratype (TCR-CDR3 length analysis) was performed with 24 TCR Vβ subfamily specific primers as well as CB primers as described previously [22]. Scoring of CDR3 profiles was performed by determining the number of contracted Vβ CDR3 size profiles in each subject's T cell CDR3 repertoire. Contracted profiles were defined as follows: oligoclonal (2–4 peaks), monoclonal (1 peak), or absent (no peaks detectable).

DNA sequencing

Gene sequencing was performed using standard techniques (GeneDx, Inc.). Sequences were analyzed using Sequencher software (Gene Codes Corporation). The reference DNA and protein sequences for Rag1 are from NIH RefSeq NM_000448.2 and NP_000439.1, respectively, and Rag2 from NM_000536.3 and NP_000527.2, respectively. Nucleotide numbering starts with 1 at the A of the ATG translation initiation codon.

Other sequencing results were identified in this patient: A homozygous single nucleotide polymorphism (SNP) was identified in Rag1, c.2459A>G which codes for p.Lys820Arg (NIH RefSNP accession rs2227973). Two homozygous, non-synonymous, coding-region SNPs were found on Rag2, p.Val154Ala (RefSNP accession rs17852002) and p.Met322Thr (RefSNP accession rs17856658).

Antibodies and plasmids

Antibodies used in this study were: anti-HA (clone HA-7, Sigma); anti-FLAG (clone M2, Sigma); anti-alpha Tubulin (clone DM1A, Abcam); and sheep anti-mouse IgG HRP-linked whole antibody (GE Healthcare). pGG49, pGG51, p3xFLAG-Rag2, and pcDNA6-myc-hisA-Rag1 were described previously [23]. Point mutations were generated by site-directed mutagenesis using Pfu Turbo DNA polymerase (Stratagene).

Extrachromosomal V(D)J recombination assays

Extrachromosomal V(D)J recombination assays were performed in Br3neo human fibroblastoid cells as described previously [24], using either pGG49 (signal-joint formation) or pGG51 (coding-joint formation) as the reporter [25]. Briefly, we transfected human fibroblast cells with murine full-length Rag1, murine full-length Rag2, and a plasmid reporter substrate and harvested the cells at 48-hours post-transfection. The plasmid DNA encodes the gene for ampicillin (Amp) resistance, and further encodes a chloramphenicol (Cam) resistance gene preceded by a transcriptional terminator flanked by recombination signal sequences. Proper recombination confers Cam resistance. The plasmid DNA was isolated from the harvested cells and transformed into bacteria. V(D)J recombination frequency was measured by comparing the number of Amp<sup>+</sup>/Cam<sup>+</sup> colonies to the number of Amp<sup>+</sup> colonies [26]. Full-length Rag2 was transiently expressed using the p3xFLAG-CMV vector (Sigma). Wildtype Rag1, Rag1<sub>V779M</sub> and Rag1<sub>R142</sub> were transiently expressed using the pcDNA6-myc-hisA vector (Invitrogen). Expression of all proteins was confirmed by Western analysis.

Proteins

Recombinant FLAG-tagged full-length Rag2 was expressed by transient transfection of 293T cells and purified as described previously [27]. Recombinant wild-type core Rag1 (aa 387–1011) and Rag1<sub>V779M</sub> were purified from Escherichia coli as described previously [28].
In vitro V(D)J cleavage assays

Rag1 and Rag1V779M were used for in vitro V(D)J cleavage assays as described previously [29]. Briefly, Rag1 (80 ng) and Rag2 (10 ng) were added to a 10 μL reaction mixture containing 25 mM HEPES (pH 7.5), 2 mM dithiothreitol, 60 mM potassium glutamate, 1 mM MnCl2, and 0.25 pmol of 32P-labeled DNA substrate. Reaction mixtures were incubated at 30°C for 2 hours, stopped with 95% formamide loading dye, separated by super-denaturing gel electrophoresis, and visualized by autoradiography.

Results

Clinical characteristics and laboratory findings

P1 was born at term to non-consanguineous parents. Starting at one month of age, he developed recurrent, waxing and waning, scaling erythroderma with recurrent skin infections requiring oral antibiotics. At approximately 4 months, due to progression of his rash, he was referred to a dermatologist and underwent a skin biopsy, which showed acute micro-vesiculating, spongiform dermatitis, dermal inflammation, and eosinophils. At 4.5 months of age, physical examination revealed global erythroderma, sparse, friable hair, generalized lymphadenopathy, and hepatosplenomegaly. Comèl-Netherton syndrome was ruled out by microscopic examination of scalp and eyelash hairs. Laboratory evaluation revealed hypoalbuminemia, peripheral eosinophilia, profound hypogammaglobulinemia, elevated IgE, absent isohemaglutinins, and lack of specific antibody production (Table 1). Lymphocyte subset analysis showed 73% CD3+ T cells (absolute 3,015/μL), absent B cells, and 27% NK cells. The number of CD8+ T cells was mildly decreased and his CD4/CD8 ratio was elevated (Table 1). T cell proliferative responses to mitogens were severely depressed (Table 1), indicating a SCID-like disorder. Maternal engraftment was ruled out by analysis of micro-satellite markers by PCR (data not shown). A clinical diagnosis of Omenn Syndrome was made, supported by the finding of oligoclonal/monoclonal TCR beta chains by spectratype analysis (Fig 1). In addition, his CD4+ T cells showed an activated, memory phenotype, expressing CD45-RO and HLA-DR on 96% and 94% of cells, respectively (Table 1).

At age 6.3 months, this patient underwent a T cell-depleted, HLA single-antigen mismatched, paternal peripheral blood transplant at Memorial Sloan-Kettering Cancer Center. Chemotherapeutic cytodestruction was achieved with intravenous busulfan (16 mg/kg) and cyclophosphamide (50 mg/kg). He received two doses of alemtuzumab (10 mg/m²/dose) prior to transplant for prophylaxis against graft rejection. Stem cells were depleted of T cells by CD34-positive selection followed by rosetting with sheep red blood cells. He received a total of 30.4 x 10⁶ CD34 cells/kg and 3.2 x 10³ CD3 cells/kg. Early post-transplant complications consisted of mucositis and persistent skin rash, which resolved by one month following HSCT. At approximately one-year after HSCT, he developed isolated severe myositis, presumed to reflect chronic GVHD, which required prolonged mechanical ventilation and treatment with steroids and cyclosporine A. He ultimately recovered, was able to breathe on his own, and was weaned off mechanical ventilation and immunosuppressive therapy. He has had no recurrence of his myositis. He was clinically well at age 5 years, when he was lost to follow-up. He has normal in vitro T cell function and specific antibody production following vaccination for Tetanus, Haemophilus influenzae, Pneumococcus, and polio virus.

Termination mutation in Rag1 (p.R142*)

On the basis of the patient history, physical exam, and laboratory findings, we diagnosed P1 with Omenn Syndrome. To determine the molecular etiology, we sequenced the Rag1 and
Rag2 genes. In addition to previously characterized polymorphisms (see Methods), P1 had a heterozygous nonsense mutation in \textit{Rag1} (c. 424C>T) (Fig 2A) resulting in an abnormal stop codon at p.Arg142Ter (Fig 2B). Sequencing of the mother’s genomic DNA revealed that this mutation was maternally inherited (data not shown).

Arg 142 is located within basic region I (aa 142–147) in the N-terminal “non-core” portion of Rag1. Assuming canonical start codon usage [31], truncation of the mRNA at this position would either result in nonsense-mediated decay of the transcript, or else could result in loss of >86% of the protein, including the core portion of the protein (aa 384–1008) that is essential for V(D)J recombination. Therefore, this nonsense mutation likely creates a null maternal allele.

**Missense mutation in Rag1 (p.V779M)**

In addition to the maternal nonsense mutation, P1 also harbored a heterozygous missense mutation in Rag1 (c.2335G>A) on the paternal allele (Fig 2C), resulting in the non-conserved amino acid substitution of p.Val779Met (Fig 2D). Val 779 is located within the core portion of Rag1, between zinc finger B (aa 728–753) and basic region IV (aa 829–843). Since Val 779 does

<table>
<thead>
<tr>
<th>Blood counts</th>
<th>Patient</th>
<th>Normal</th>
</tr>
</thead>
<tbody>
<tr>
<td>White blood cell count (cells/µL)</td>
<td>16,270</td>
<td>7,000–16,000</td>
</tr>
<tr>
<td>Absolute lymphocyte count (cells/µL)</td>
<td>4,130</td>
<td>3,900–9,000</td>
</tr>
<tr>
<td>Absolute eosinophil count (cells/µL)</td>
<td>5,710</td>
<td>0–400</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Lymphocyte populations % (cells/µL)</th>
<th>Patient</th>
<th>Normal (10th to 90th percentile)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD3 73% (3,015)</td>
<td>51–77% (2,500–5,600)</td>
<td></td>
</tr>
<tr>
<td>CD4 (CD3 pos) 67% (2,767)</td>
<td>35–56% (1,800–4,000)</td>
<td></td>
</tr>
<tr>
<td>CD8 (CD3 pos) 8% (330)</td>
<td>12–23% (5,90–1,600)</td>
<td></td>
</tr>
<tr>
<td>CD19 0% (0)</td>
<td>5–10%</td>
<td></td>
</tr>
<tr>
<td>CD16 (CD3 neg) 27% (1,115)</td>
<td>5–15%</td>
<td></td>
</tr>
<tr>
<td>CD3 HLA-DR+ 94%</td>
<td>2–10%</td>
<td></td>
</tr>
<tr>
<td>CD3 CD45-RO 96%</td>
<td>3–16%</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Immunoglobulins</th>
<th>Patient</th>
<th>Normal</th>
</tr>
</thead>
<tbody>
<tr>
<td>IgG (mg/dL) 137</td>
<td>200–1200</td>
<td></td>
</tr>
<tr>
<td>IgA (mg/dL) &lt;7</td>
<td>5–46</td>
<td></td>
</tr>
<tr>
<td>IgM (mg/dL) 52</td>
<td>10–90</td>
<td></td>
</tr>
<tr>
<td>IgE (IU/mL) 5,550</td>
<td>10–30</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Lymphocyte proliferation</th>
<th>Background (cpm ± std)</th>
<th>134 +/- 37</th>
<th>1,012 +/- 566</th>
</tr>
</thead>
<tbody>
<tr>
<td>ConA (cpm ± std) 2,133 +/- 600</td>
<td>86,229 +/- 16,286</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHA (cpm ± std) 4,140 +/- 532</td>
<td>83,383 +/- 6,314</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PWM (cpm ± std) 10,100 +/- 1,560</td>
<td>63,575 +/- 4,996</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Background (cpm ± std) 94 +/- 25</td>
<td>495 +/- 180</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tetanus (cpm ± std) 445 +/- 30</td>
<td>14,213 +/- 3,528</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Candida (cpm ± std) 309 +/- 214</td>
<td>24,937 +/- 5,727</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Normal values from the Children’s Hospital Laboratory, the Cincinnati Children’s Hospital Laboratory, or from reference [30].

doi:10.1371/journal.pone.0121489.t001

Table 1. Peripheral blood analysis of P1 at time of initial presentation (age 4½ months) is consistent with Omenn’s Syndrome.
not fall within any known Rag1 functional motifs, it was unclear whether this mutation would affect the function of the Rag1/2 complex.

Rag1\(_{R142^*}\) is a null mutant and Rag1\(_{V779M}\) is a hypomorphic mutant

To test whether the p.R142\(^*\) and p.V779M mutations impair the function of Rag1, we examined the ability of Rag1\(_{R142^*}\) and Rag1\(_{V779M}\) to perform V(D)J recombination in cultured human cells using an extrachromosomal V(D)J recombination assay[24]. Fibroblast cell lines were then transfected with an expression vector encoding for either full-length wild-type Rag1, Rag1\(_{V779M}\), or Rag1\(_{R142^*}\), plus both full-length Rag2 and an exogenous recombination substrate to detect either signal joints (pGG49) or coding joints (pGG51) [29]. Despite being expressed at comparable levels to wild-type Rag1 (Fig 3A), Rag1\(_{V779M}\) exhibited a dramatic deficiency (>99%) in V(D)J recombination activity (Fig 3B and 3C). Nonetheless, some residual activity was observed. The deficiency was observed on both types of substrates tested: those that form signal joints (0.73% of wild-type) and those that form coding joints (0.18% of wild-type) (Fig 3B and 3D). Although it has been reported that premature stop codons in the N-terminal region of Rag1 can be rescued by internal methionine usage [31], we observed no V(D)J recombination activity for Rag1\(_{R142^*}\) (Fig 3B), and we were unable to detect expression of the Rag1\(_{R142^*}\) protein. Therefore, the p.R142\(^*\) mutation observed in P1 creates a null allele, while the p.V779M substitution observed in P1 is a hypomorphic mutation that profoundly impairs Rag1’s ability to catalyze V(D)J recombination.
Compound Heterozygous Mutation of Rag1 Leading to Omenn Syndrome

Fig 2. 

**A.** Sequencing chromatogram demonstrating the presence of a heterozygous c.424C>T mutation. **B.** Alignment of the wildtype and mutant Rag1 cDNA and protein sequences. c.424C>T creates a premature stop codon at position 142 of the protein. **C.** P1 harbors a paternally inherited c.2335G>A mutation, resulting in the non-synonymous coding mutation p.V779M. Sequencing chromatogram demonstrating the presence of a heterozygous c.2335G>A mutation. **D.** Alignment of the wildtype and mutant Rag1 cDNA and protein sequences. c.2335G>A creates a missense p.V779M mutation in the Rag1 protein.

doi:10.1371/journal.pone.0121489.g002
Rag1V779M is functional in V(D)J cleavage assays in vitro

Having observed that Rag1V779M is deficient in V(D)J recombination activity, we wanted to test whether the p.V779M mutation impairs V(D)J cleavage. To generate a DNA double-strand break at a recombination signal sequence, the Rag1/2 complex must bind to the RSS and then catalyze both nicking and hairpinning. To assay for a defect in one of these steps of V(D)J recombination, we tested the ability of recombinant wild-type and mutant core Rag1 proteins (aa 387–1011) to catalyze V(D)J cleavage in vitro. The recombinant proteins, which expressed and purified equally well (Fig 4A), were incubated with full-length recombinant Rag2 plus a32P-labeled DNA substrate that contains a recombination signal sequence. Surprisingly, Rag1V779M catalyzed V(D)J cleavage at wild-type levels, generating both nicked and hairpinned products (Fig 4B and 4C). Thus, the p.V779M mutation does not impair Rag1/2-mediated RSS binding or cleavage.

### Table

<table>
<thead>
<tr>
<th>Substrate</th>
<th>Rag1</th>
<th>AmpR (x10^5) (a)</th>
<th>AmpR CamR (b)</th>
<th>% Rec. (c)</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>WT</td>
<td>810</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>pGG49</td>
<td>WT</td>
<td>832</td>
<td>93,000</td>
<td>11.17</td>
</tr>
<tr>
<td></td>
<td>V779M</td>
<td>874</td>
<td>661</td>
<td>0.08</td>
</tr>
<tr>
<td></td>
<td>R142X</td>
<td>843</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>pGG51</td>
<td>None</td>
<td>952</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>WT</td>
<td>1100</td>
<td>38,000</td>
<td>3.45</td>
</tr>
<tr>
<td></td>
<td>V779M</td>
<td>1206</td>
<td>67</td>
<td>0.006</td>
</tr>
<tr>
<td></td>
<td>R142X</td>
<td>1027</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

(a) Total # of substrate plasmids analyzed
(b) # of recombed substrate plasmids analyzed
(c) Percent recombination = # of recombed plasmids (AmpR/CamR) / total # of substrate plasmids (AmpR)

**Fig 3. Rag1R142 is a null mutant and Rag1V779M is a hypomorphic mutant.**

A. Western analysis of Flag-tagged full-length Rag1 proteins expressed in Br3neo human fibroblast cells confirms that the wild-type (Rag1) and mutant (Rag1V779M) proteins are expressed at comparable levels in vivo. B. Representative recombination data from using the indicated constructs for transient V(D)J recombination assays in Br3neo cells. C. Absolute recombination activity using wild-type Rag1 (hatched) or the p.V779M mutant (shaded) with signal-joint substrates (left) or coding-joint substrates (right). Results represent the mean ± s.d. of six independent experiments. D. Normalized recombination activity of the p.V779M mutant. Recombination activity of the p.V779M mutant on each substrate was normalized to the activity of wild-type Rag1. Results represent the mean ± s.d. of six independent experiments.

doi:10.1371/journal.pone.0121489.g003
Fig 4. Rag1\textsubscript{V779M} has wild-type V(D)J cleavage activity. 

A. Wild-type and mutant Rag1 proteins express and purify equally well. Coomassie stained gel of wild-type (Rag1) and mutant (Rag1\textsubscript{V779M}) recombinant core Rag1 proteins purified from E. coli. A serial dilution series (5-fold dilutions between lanes) is shown for each protein.

B. The p.V779M mutant protein catalyzes wild-type V(D)J cleavage \textit{in vitro}. Cleavage reactions were
Discussion

We present here an infant boy with Omenn Syndrome bearing compound heterozygous mutations of Rag1: a nonsense mutation on the maternal allele (p.R142*C3) and a missense mutation on the paternal allele (p.V779M). Functional analysis of these Rag1 alleles revealed that the p.R142* mutation creates a null allele, while the p.V779M substitution is a hypomorphic mutation that severely impairs V(D)J recombination in vivo. However, biochemical analysis demonstrated that the p.V779M substitution does not impair V(D)J cleavage in vitro, indicating that this mutation is not a catalytic mutation.

Mechanism of Omenn Syndrome

Over the past 15 years, many different Rag mutations have been shown to cause Omenn Syndrome [6,13,32,33,34]. Indeed, more than 90% of Omenn Syndrome cases are attributable to hypomorphic mutations in Rag1 and Rag2 [35]. These hypomorphic Rag mutants can be broadly classified into two categories: those that exhibit impaired V(D)J cleavage in vitro—for example, mutants that are impaired in Rag1-Rag2 complex formation [11,36,37], DNA binding[11], or RSS nicking [38]; those that exhibit wild-type V(D)J cleavage activity in vitro but impaired V(D)J recombination in vivo—for example, mutants that are impaired in chromatin-binding [23,39] or in rejoining the broken DNA ends generated during V(D)J cleavage [40,41,42,43].

P1’s nonsense mutation on the maternal allele (p.R142*) would, if translated, remove all of the functional regions in Rag1 described above. As such, it either produces a severely truncated, nonfunctional protein or the message is deleted by nonsense-mediated decay. Therefore, the p.R142* mutation clearly falls in the first category of mutations that impair both V(D)J cleavage in vitro and V(D)J recombination in vivo.

P1’s missense mutation on the paternal allele (p.V779M) is more interesting in that it appears to leave the previously described functional regions of Rag1 intact (Fig 5), and yet, it severely impairs V(D)J recombination (Fig 3). The simplest explanation for this phenotype would be that the p.V779M substitution disrupts V(D)J recombination by causing misfolding of the protein, similar to other Rag1 mutants [44]. However, our in vitro V(D)J cleavage assays demonstrate that Rag1V779M is fully functional in V(D)J cleavage, arguing against any substantial defect in protein folding. While a previous study suggested that Rag1V779M might be modestly impaired in 12-RSS nicking in vitro [38], we found no apparent defect in the catalytic activity of this mutant. Although it is difficult to account for differences in protein purifications and experimental assay conditions, based on the robust cleavage activity that we observed, we would argue that the p.V779M mutation likely falls in the second category of mutations that exhibit wild-type V(D)J cleavage activity in vitro, but impaired V(D)J recombination in vivo. It is possible that Rag1V779M is deficient in V(D)J recombination because it fails to interact with some key regulatory factor in vivo, and is therefore deficient in coupled cleavage, analogous to the Rag2 mutations described in other Omenn Syndrome patients [23,45]. Alternatively, it is possible that Rag1V779M impairs the rejoining of the broken DNA ends generated during V(D)J cleavage. Along these lines, it is interesting to note that Rag1V779M is more severely impaired in coding joint formation than it is in signal joint formation (Fig 3D), suggesting that Rag1V779M...
may be a joining-deficient mutant that affects the post-cleavage stage of V(D)J recombination, analogous to previously identified Rag mutants \[40,41,42,43\]. Future studies will test the hypothesis that hypofunctional Rag1 and Rag2 mutants can confer susceptibility to Omenn Syndrome by impairing the post-cleavage stage of V(D)J recombination.

### Function of the Rag1 C-terminal domain

Previous studies using limited proteolysis have identified two potential domains within the core portion of human Rag1: the central domain (aa 531–763; purple bar); and the C-terminal domain (aa 764–983; orange bar). Rag1 contains four basic regions (B1: aa 142–147; BII: aa 219–237; BIII: aa 244–252; BIV: aa 829–843; gray), a RING finger (aa 293–331; red), two zinc fingers (ZFA: aa 356–379; ZFB: aa 728–753; blue), a nonamer DNA-binding region (NBR: 387–457; dark yellow), a nuclear localization signal (NLS: aa 972–976; green), an Asp-Asp-Glu active site motif (D603, D711, E965), and two C-terminal zinc-binding sites (C905/C907 and H940/H945). The four basic regions serve as binding sites for the nuclear transport proteins Srp1 and Rch1. The RING finger functions as an E3 ubiquitin ligase and, together with zinc finger A, mediates Rag1 multimerization. Zinc finger B is thought to function as a Rag2 binding site. The positions of R142 and V779 are indicated.

doi:10.1371/journal.pone.0121489.g005

Fig 5. Overall domain structure of the human RAG1 protein. The human RAG1 protein is 1043 amino acid long and consists of a core region (aa 387–1011; yellow) and non-core regions (aa 1–386 and 1012–1043; white). There are two potential domains within the core region of Rag1: the central domain (aa 531–763; purple bar); and the C-terminal domain (aa 764–983; orange bar). Rag1 contains four basic regions (B1: aa 142–147; BII: aa 219–237; BIII: aa 244–252; BIV: aa 829–843; gray), a RING finger (aa 293–331; red), two zinc fingers (ZFA: aa 356–379; ZFB: aa 728–753; blue), a nonamer DNA-binding region (NBR: 387–457; dark yellow), a nuclear localization signal (NLS: aa 972–976; green), an Asp-Asp-Glu active site motif (D603, D711, E965), and two C-terminal zinc-binding sites (C905/C907 and H940/H945). The four basic regions serve as binding sites for the nuclear transport proteins Srp1 and Rch1. The RING finger functions as an E3 ubiquitin ligase and, together with zinc finger A, mediates Rag1 multimerization. Zinc finger B is thought to function as a Rag2 binding site. The positions of R142 and V779 are indicated.

### Author Contributions

Conceived and designed the experiments: AM CB KY JM MJB. Performed the experiments: AM CB KY. Analyzed the data: AM CB KY MJB. Contributed reagents/materials/analysis tools: TS FB MO MJB. Wrote the paper: AM MO MJB.
3. van Gent DC, van der Burg M. Non-homologous end-joining, a sticky affair. Oncogene. 2007; 26: 7731–7740. PMID:18066085


40. Qiu JX, Kale SB, Yarnell Schultz H, Roth DB. Separation-of-function mutants reveal critical roles for RAG2 in both the cleavage and joining steps of V(D)J recombination. Mol Cell. 2001; 7: 77–87. PMID: 11172713


45. Ramon-Maiques S, Kuo AJ, Carney D, Matthews AG, Oettinger MA, Gozani O, et al. The plant homeo-
domain finger of RAG2 recognizes histone H3 methylated at both lysine-4 and arginine-2. Proc Natl
Acad Sci U S A. 2007; 104: 18993–18998. PMID: 18025461

46. Arbuckle JL, Fauss LA, Simpson R, Ptaszek LM, Rodgers KK. Identification of two topologically inde-
pendent domains in RAG1 and their role in macromolecular interactions relevant to V(D)J recombi-

47. Cuomo CA, Kirch SA, Gyuris J, Brent R, Oettinger MA. Rch1, a protein that specifically interacts with
the RAG-1 recombination-activating protein. Proc Natl Acad Sci U S A. 1994; 91: 6156–6160. PMID:
8016130

RNA binding properties of the V(D)J recombination-activating proteins RAG1 and RAG2. Immunity.
1995; 3: 715–726. PMID: 8777117

49. Landree MA, Wibbenmeyer JA, Roth DB. Mutational analysis of RAG1 and RAG2 identifies three cata-
ytic amino acids in RAG1 critical for both cleavage steps of V(D)J recombination. Genes Dev. 1999;
13: 3059–3069. PMID: 10601032

50. Kim DR, Dai Y, Mundy CL, Yang W, Oettinger MA. Mutations of acidic residues in RAG1 define the ac-

51. Gwyn LM, Peak MM, De P, Rahman NS, Rodgers KK. A zinc site in the C-terminal domain of RAG1 is
PMID: 19500590

nation activity and genotype-phenotype correlation in human recombination-activating gene 1 deficien-